This report delivers a targeted analysis of the anaemia treatment landscape in chronic kidney disease (CKD) within Japan, one of the world’s most mature nephrology markets and an early adopter of the HIF prolyl hydroxylase inhibitors (HIF-PHIs). Leveraging tracked market data between 2020-2022, this analysis provides evidence-based insights into shifting treatment dynamics following the 2019 launch of roxadustat.